Trial Condition(s):

N/A

BAY 43 9006 in combination with doxorubicin chemotherapy in patients

Bayer Identifier:

10916

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available

Study Completed

Trial Purpose

Primary objective: To define the safety profile of continuously administered
sorafenib in combination with 3-weekly administrations of doxorubicin in subjects with advanced, refractory solid tumors;
Secondary objectives were
• To evaluate the pharmacokinetics and pharmacodynamics of sorafenib in combination with doxorubicin and vice versa;
• To determine the objective tumor response rate including complete and partial response rates based on WHO criteria.

Inclusion Criteria

No Inclusion Criteria Available

Exclusion Criteria

No Exclusion Criteria Available

Trial Summary

Enrollment Goal

Trial Dates

September2002

March2008

Phase

Could I receive a placebo?

Products

Nexavar (Sorafenib, BAY43-9006)

Accepts Healthy Volunteers

Where to Participate

Locations

Locations

N/A

Bayer Identifier:

ClinicalTrials.gov Identifier:

EudraCT Number:

EU CT Number:

Trial Purpose

Key Participation Requirements

sex

age

33 Years

78 Years

Inclusion Criteria

Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Trial Summary

Enrollment Goal

Trial Dates

Phase

Could I receive a placebo?

Products

Accepts Healthy Volunteers

Where to Participate

For details, please refer to trial results

Additional Information